Table 4 Average annual healthcare costs of asthma patients receiving medium- or high-dose Symbicort or Seretide Diskus therapy (USD)
From: Pitfalls associated with the therapeutic reference pricing practice of asthma medication
Group | Treatment | Number of patients | Expenditure (USD) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Maintenance therapy | Reliever medication | Exacerbation medication | Total medication | Special* outpatient care | Total outpatient care | Special† inpatient care | Total inpatient care | Total‡ | |||
High dose | Symbicort | 3 888 | 851.7 | 17.8 | 65.9 | 2140.2 | 42.7 | 220.1 | 59.2 | 760.2 | 3120.6 |
Seretide | 5 869 | 796.9 | 21.3 | 77.9 | 2540.3 | 43.1 | 228.6 | 75.2 | 786.6 | 3555.6 | |
raw difference (Sym vs Ser) | 54.8 | −3.6 | −12.0 | −400.1 | −0.4 | −8,5 | −16.0 | −26.4 | −435.0 | ||
adjusted§ difference | 53.3 | −3,7 | −15.9 | −125.8 | −0.5 | −9.2 | −14.1 | −11.4 | −230.9 | ||
95% CI of the adjusted difference | 25.1; 81.6 | −5.3; -2.0 | −23.3; -8.5 | −242.3; -9.2 | −3.0; 1.9 | −29.6; 11.3 | −33.6; 5.4 | −140.9; 118.1 | −628.3; 166.5 | ||
p-value | 0.001 | <10-3 | <10-3 | 0.04 | 0.7 | 0.4 | 0.1 | 0.9 | 0.2 | ||
Medium dose | Symbicort | 11 651 | 575.8 | 11.6 | 43.3 | 1563.0 | 40.2 | 208.2 | 43.1 | 510.0 | 2281.2 |
Seretide | 6 391 | 575.3 | 13.5 | 40.5 | 1590.5 | 38.9 | 211.2 | 30.0 | 494.4 | 2296.1 | |
raw difference (Sym vs Ser) | 0.6 | −1.9 | 2.7 | −27.5 | 1.3 | −3.0 | 13.1 | 15.6 | −14.9 | ||
adjusted§ difference | 0.6 | −2.2 | 3.4 | 9.0 | 1.7 | 3.8 | 14.2 | 34.9 | 93.1 | ||
95% CI of the adjusted difference | −20.0; 21.2 | −4.0; -0.5 | −0.8; 7.6 | −68.7; 86.6 | 0.2; 3.14 | −12.3; 19.9 | 3.9; 24.4 | −18.6; 88.3 | −87.9; 274.15 | ||
p-value | 0.96 | 0.02 | 0.1 | 0.8 | 0.03 | 0.6 | 0.01 | 0.2 | 0.3 | ||